Amylyx Pharmaceuticals, Inc. AMLX
29.49
(0.65)
(2.16%)
as of 25 Sep
- Market cap
- $3.8B
- P/E
- 0.0×
Follow AMLX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (74.73%) | (63.26%) | (61.59%) | (56.52%) |
+8 more TTM periods Free account |
|
| (66.25%) | (58.49%) | (55.00%) | (48.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(64.61%) | (55.75%) | (48.04%) | (45.51%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.18) | (1.13) | (1.31) | (1.66) | |
Free Cash Flow |
(130.72) | (124.53) | (123.48) | (154.52) | |
Capital Expenditures |
(4.14) | (4.13) | (0.14) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(25.84%) | (21.78%) | (19.82%) | (22.85%) | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.83 | 0.80 | 0.85 | 1.03 | |
Depreciation/Fixed assets |
(18.88) | (18.70) | (16.13) | (14.24) | |
Capex/Depreciation |
1.10 | 1.04 | 0.03 | 0.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.14) | (1.09) | (1.30) | (1.65) | |
Capex per Share |
(0.04) | (0.04) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates